SCHEMBL3056037

SCHEMBL3056037

Nc1ccc(Oc2cccc3c2ccn3CC(=O)N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 4/20 0.53
HTT P42858 3/20 0.49
USP2 O75604 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LOXL2 Q9Y4K0 4/20 0.48
TDP1 Q9NUW8 2/20 0.47
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ABCB11 O95342 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
ADRA2A P08913 1/20 0.45
CYP2D6 P10635 1/20 0.45
CHRM1 P11229 1/20 0.45
TBXA2R P21731 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3065797 0.86 ALDH1A1 (0.48) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3056414 0.84 MEN1 (0.48) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3059769 0.84 LMNA (0.46) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3047408 0.83 TDP1 (0.47) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3139361 0.77 KDM4E (0.50) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3142784 0.77 KMT2A (0.46) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3142160 0.77 LMNA (0.55) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3139370 0.77 KDM4E (0.51) LMNAMEN1KMT2AKDM4EALDH1A1
Hydrochloric Acid SCHEMBL3134931 0.76 CYP3A4 (0.56) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL3142788 0.76 SMN1; SMN2 (0.51) LMNAMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 LMNA 1184/4885MEN1 275/4885KMT2A 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.